Autres langues Ocuphire Pharma, Inc.

Actions

OCUP

US67577R1023

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 17/05/2024			Varia. 5j.	Varia. 1 janv.
1,685 ^USD	-2,88%		-2,03%	-44,02%

10/05	Ocuphire Pharma, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
11/04	Ocuphire Pharma recrute le premier patient dans l'essai de phase 3 du traitement de l'acuité visuelle	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Diabetic Retinopathy Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)	15/05
Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update	13/05
Ocuphire Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05
Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update	10/05
Ocuphire Pharma to Present at the Aegis Virtual Conference	06/05
Ocuphire Pharma Announces Presentation on APX3330 at the ARVO 2024 Annual Meeting	06/05
Ocuphire Pharma to Present at the Aegis Virtual Conference	03/05
Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting	22/04
Ocuphire Pharma Enrolls 1st Patient in Phase 3 Trial of Visual Acuity Treatment	11/04
First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery	11/04
Ocuphire Pharma, Inc. Announces Global License Agreement with Viatris Inc	11/04
Ocuphire Pharma, Inc. Announces the Enrollment of the First Subject in the LYNX-2 Phase 3 registration study	11/04
Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris	01/04
Ocuphire Pharma, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	08/03
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update	08/03
Ocuphire Pharma to Present in the BIO CEO and Investor Conference	26/02
Ocuphire Pharma to Present in the BIO CEO & Investor Conference	23/02
Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	15/02
Ocuphire Pharma Appoints CFO, Science Chief	14/02
Ocuphire Pharma Strengthens Leadership Team with Key Appointments	14/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Ocuphire Pharma, Inc.

Actions

OCUP

US67577R1023

Autres langues

Filtres